Mesenchymal stem cells added to second-line therapy improve response and failure-free survival in steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A meta-analysis of randomized controlled trials
BackgroundSteroid-refractory acute graft-versus-host disease (aGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT), with limited effective treatment options. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic...
Furkejuvvon:
| Váldodahkkit: | , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Frontiers Media S.A.
2025-11-01
|
| Ráidu: | Frontiers in Oncology |
| Fáttát: | |
| Liŋkkat: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1704963/full |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
